Owlstone Medical Raises $15M in Funding

Owlstone Medical, a UK-based diagnostics company developing a breathalyzer for disease, raised $15 million in funding led by Horizons Ventures and Aviva Ventures. The funds will be used to bring the company's lung cancer Breath Biopsy test to market, deepen the early detection pipeline, and grow its precision medicine services.

Owlstone Medical Secures $15 Million for Breathalyzer Technology

Owlstone Medical Ltd is a Cambridge, England, UK-based diagnostics company developing a breathalyzer for disease. The company is advancing the Breath Biopsy platform for early detection and precision medicine, with applications in cancer and a wide range of other conditions. The platform is currently being evaluated in the world’s largest breath-based clinical trials for two of the most common cancer killers globally – lung and colorectal cancer. It is also being used in the PAN cancer trial, a collaboration with Cancer Research UK which is studying the early detection of eight different cancer types in breath.

Owlstone Medical is a UK-based diagnostics company developing a breathalyzer for disease, with applications in cancer and other conditions.

7 years ago

Owlstone Medical Secures $15 Million for Breathalyzer Technology

ProblemHealthcare

Solution

Covered on